より標的性の高い抗がん免疫細胞を作製(Researchers grow immune cells with more targeted cancer-fighting abilities)

ad

2026-03-10 カリフォルニア大学バークレー校(UCB)

カリフォルニア大学バークレー研究チームは、がん細胞より正確攻撃できる免疫細胞作製する新しい培養手法開発した。研究では、免疫細胞成長環境刺激条件精密制御することで、腫瘍細胞標的する能力高めT細胞効率増殖させることに成功した。これにより、従来免疫療法より高い標的持つ細胞作り出す可能性た。開発方法は、がん免疫療法用いる細胞製造プロセス改善つながり、患者ごと最適化細胞治療実現促進する技術として期待いる。

<関連情報>

人工ハイドロゲルプラットフォームにおける剛性と接着受容体の結合の調節によるT細胞増殖の調整可能な促進 Tunable Enhancement of T Cell Expansion Through Modulation of Stiffness and Adhesion Receptor Engagement in an Engineered Hydrogel Platform

Niroshan Anandasivam, Rabia Ali, Lordean Gustinvil, Matthew J. Rosenwasser, Iain E. Dunlop, Derfogail Delcassian
Advanced Materials  Published: 08 January 2026
DOI:https://doi.org/10.1002/adma.202505965

より標的性の高い抗がん免疫細胞を作製(Researchers grow immune cells with more targeted cancer-fighting abilities)

ABSTRACT

Adoptive T cell therapies (ACT) are an important class of oncology treatments that require ex vivo T cell expansion for clinical success. Technologies that can control both phenotype and yield in expanded cell products are highly desired. Here, we develop a new hydrogel scaffold for controlled T cell expansion with yields of up to 2000× fold in two weeks, compared to other hydrogel constructs (≈250×) and Dynabeads (≈1200×). Our 2D polyethylene glycol diacrylate (PEGDA) hydrogel scaffold is cross-linked with streptavidin moieties to present various biotinylated ligands to cells with controlled hydrogel stiffness (PEGDA-Strep). Using this platform, we demonstrate that combining substrate stiffness with adhesion receptor ligands (aLFA-1 or aCD2) dictates T cell activation and proliferation. On stiff substrates, these ligands drove expansions 49% (aLFA-1) and 68% (aCD2) greater than Dynabeads with comparable T cell products, preceded by elevated metabolic and transcriptional activity. Notably, while stiff substrates increased yield, soft substrates produced T cells with superior antigen-specific killing selectivity. These findings highlight the role of mechanical sensing in T cell-APC interactions and suggest improved manufacturing methods for adoptive T cell therapy (ACT).

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました